Antibody Applications: Therapeutics and Diagnostics Analysis

This report delves into the dual application of antibodies in both therapeutic and diagnostic contexts. It begins by outlining the fundamental principles of monoclonal antibodies and their significance in various medical applications. The report then explores the efficiency of using the same antibody for both purposes, acknowledging the potential benefits but also highlighting practical considerations. Two specific examples are presented: Anti-erbB-2 antibodies used for both diagnostics and the treatment of breast cancer, and Anti-Adalimumab (Humira) used for various conditions. The report discusses the side effects of each antibody, providing a balanced view of their therapeutic potential and associated risks. The analysis concludes with a discussion of the factors that may influence the straightforwardness of using antibodies for both applications, such as specificity, target tissue uptake, and adverse reactions.

USE OF ANTIBODY FOR THERAPEUTICS AND DIAGNOSTICS
Antibodies are important part of many diagnostic assays and therapeutic
applications. Monoclonal antibodies recognize a single epitope within an antigen and are
generated from a single clone of B-cells and they consist of identical antibody molecules
specific to a single epitope. As a result they can be used for diagnosis and screening.
Persistent efforts by scientists and clinicians have improved uptake in target tissue,
reduced adverse reactions and toxicities, and developed successful radiolabeling
techniques. Advances in biotechnology, especially genetic engineering, provide methods
to manipulate the antibody molecule to produce human antibodies. We shall discuss the
two of them used for both therapeutic and diagnostics application ( Byrne, Conroy,
Whisstock & O’Kennedy, 2013)
1. Anti-erbB-2 antibodies is used both for diagnostics and for therapeutic purposes.
(Antigen alternative name CD340). The anti-erbB-2 / HER-2 is an antibody for use in
Western blot, immunoprecipitation and immunohistochemistry. It is a polyclonal
antibody. Anticose anti-erbB-2 trastuzumab is used for treatment of breast cancer .
Diarrhea and skin rashes are the side effects of anti-erB-2 antibodies (King, Kasprzyk &
Bird ,1996).
2. Anti-Adalimumab, brand name Humira is a medicine used for treatment of psoriatic
arthritis, rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, Crohn's disease,
uveitis and juvenile idiopathic arthritis. Used to maintain remission of fever in adults
affected due to Crohn's disease who fail to respond to other medications. It is applied by
injection under the skin ( Ecker, Jones & Levine, 2015).
The side effects are pain at the site of injection, upper respiratory tract infections, skin
rash , headache, serious anaphylaxis, hepatitis B reactivation, liver failure, infections,
heart failure, and aplastic anemia.
References
Byrne, H., Conroy, P. J., Whisstock, J. C., & O’Kennedy, R. J. (2013). A tale of two
specificities: bispecific antibodies for therapeutic and diagnostic
applications. Trends in biotechnology, 31(11), 621-632.
Ecker, D. M., Jones, S. D., & Levine, H. L. (2015, January). The therapeutic monoclonal antibody
market. In MAbs (Vol. 7, No. 1, pp. 9-14). Taylor & Francis.
King, C. R., Kasprzyk, P. G., & Bird, R. E. (1996). U.S. Patent No. 5,587,458.
Washington, DC: U.S. Patent and Trademark Office.